Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Placebo-controlled Trial to Assess Efficacies of EMPAgliflozin and Personalized Dietary Counselling for Kidney STONE Prevention in Patients With Calcium Kidney Stones Acronym: EMPASTONE Trial

NCT06653738 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT06653738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06653738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Placebo-controlled Trial to Assess Efficacies of EMPAgliflozin and Personalized Dietary Counselling for Kidney STONE Prevention in Patients With Calcium Kidney Stones Acronym: EMPASTONE Trial
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Phase 3
Overall status
Recruiting
Start date
July 2, 2026
Completion date
September 30, 2030
Enrollment
400 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

dietary exposure, kidney stone, nephrolithiasis